In 1998, Clay Siegall co-founded Seattle Genetics and is currently the chief executive officer, president, and chairman of the board of the organization. Siegall is a trained scientist with a focus on targeted cancer therapies. He established Seattle Genetics on the background of rigorous research, scientific innovation, passion for assisting patients, and drug development practices. Siegall has spearheaded the organization to its present leadership status by developing ADCs- antibody drug conjugates and securing the approval of the 2011 FDA for its first ADC item ADCETRIS (brentuximab vedotin). By working together with Takeda Pharmaceutical Company, the name (ADCETRIS) is currently a world brand that has been accepted in over 65 countries. The organization (Seattle Genetics) is also developing a diverse ADCs proprietary for Cancer treatment.
Under the headship of Clay Siegall, Seattle Genetics has acquired multiple strategic licenses while applying its ADC technology. The organization currently works together with other firms such as Genentech (Roche), Pfizer, AbbVie, and GlaxoSmithKline. Across collaborating and internal programs, there are over 20 ADCs within clinical development exercises that are utilizing Seattle Genetics’ technology. Another key achievement of Siegall in Seattle Genetics is the spearheading of capital-raising practices that have secured over $1.2 billion through private and public financings, notwithstanding its first public offering in 2001.
Before he co-founded Seattle Genetics, Siegall operated in other companies, which added to his experience. For instance, from 1988 to 1991, he worked at National Cancer Institute and from 1991 to 1997, he operated at the Bristol-Myers Squibb Pharmaceutical Research Institute. He is also part of the board of directors of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. Siegall is also a recipient of several awards.
According to Siegall, the idea of Seattle Genetics came from the desire to offer patients better treatment services after watching his dad suffer from cancer, which later killed him. It is at this time that he realized that the oncology sector and cancer treatment centers had limited tools. After earning a Doctorate at George Washington University, he later learned how to operate a Company after working with various organizations. His goal is to offer better treatment to cancer patients to save lives.